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TNF isnow recognized as atypical member ofthecytokine family with pleiotropic
cellular activities (1-3) . One of the main questions regarding TNF action relates
to the intracellular controlmechanisms that regulate TNF response patterns in both
qualitative and quantitative terms . Though expression of TNF-specific membrane
receptors is given in most normal and malignant tissues (4, 5), there is increasing
evidence that controlmechanisms ofTNF responsiveness are effective at both receptor
andpostreceptor levels . For example, control at a postreceptor level is suggested from
recent data showing that TNF-induced modulation of transcriptional programs of
U937 cells was dependent on the differentiation status of the cell (6) and associated
with the presence of a cytosolic phosphoprotein (pp26), a presumed TNFspecific
signal transducer (7) . Moreover, dominance of resistance to TNFmediated growth
inhibition ofsomatic cell hybridsbetweenTNFsensitive and -resistant cell lines was
also shownto bedue to postreceptor control (8, 9) . At the receptor level, there exists
a quantitative relationship between receptor number and sensitivity ofagivenTNF
responsive cell (3) . Thus, we have shown that a non-tissue-specific, protein kinase
C (PKC)'-dependent control mechanism exists that downregulates TNF receptor
(TNFR) function by affecting receptor affinity (10, 11). This PKC-induced trans-
modulation ofTNFR is associated with reduction in TNF sensitivity, which can
be fully recovered by de novo synthesis and membrane expression of receptor pro-
tein (10) . To date, little is known about the mechanisms regulatingTNFR expres-
sion, which is apparently constitutive in most tumor cells including leukemia and
lymphoma cell lines (4, 5) . In contrast, in normal peripheral bloodT lymphocytes,
TNF-R expression is activation dependent (12) . IFN-y has been recognized as one
of the exogenous stimulatory signals ofTNFR expression (5, 13) . We have here
identified protein kinase A (PKA) as one of the endogenous regulatory elements
that control TNFR expression by a mechanism independent of and antagonistic
to the previously described PKC-mediated control of receptor affinity (10) .
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Materials and Methods
Reagents. N-2-0-dibutyryladenosine 3'5'cyclic monophosphate (DBcAMP), 8-bromo-
adenosine 3'5'cyclic monophosphate (8-Br-cAMP), 3-isobutyl-l-methyl-xanthine (IBMX) and
1-oleyl-2-acetyl rac-glycerol (OAG) were from Sigma Chemical Co., Munich, FRG. N-[2-
(methylamino) ethyl]-5-isoquinolinesulfonamide dihydrochloride (H-8)was from Seikagaku
America, Inc., St. Petersburg, FL.
Cytokines.
￿
Purified rTNF-a, lymphotoxin (LT, TNF-/3), IFN-'Y, and IFN-a were provided
by Dr. G. Adolf, Boehringer Ingelheim, Vienna, Austria. TNF, LT, IFN-y and IFN-a were
iodinated by the lactoperoxidase method as described (5, 14), with the exception that iodina-
tion ofIFN-a was performed in a sodium acetate buffer at pH 5.5. The specific radioactivity
of the radioiodinated cytokines was 20-50 pCi/ug. Bioactivity of the iodinated material was
determined as described and was always >60% (5).
Cells and Culture Conditions.
￿
All cell lines used in this study were obtained from the Amer-
ican Type Culture Collection (Rockville, MD). Cells were maintained in Click's/RPMI 1640
culture medium (Biochrom, Berlin, FRG) supplemented with 5% FCS, 10 mM Hepes, pH
7.3, and 50 /M 2-ME (5, 10).
PBMC were isolated from Ficoll-separated blood leukocytes by plastic adherence for 2 h
at 37'C. Purity of the preparations obtained was >95%, as controlled by direct immunofluores-
cence flow cytometry (EPICS C) using the Mo 2 antibody (Coulter Electronics, Krefeld,
FRG). After cell culture, the adherent cells were kept for 15 min on ice and subsequently
removed by vigorous pipetting.
BindingAssays.
￿
Determinations ofbinding capacitiesusing iodinated cytokines were per-
formed in triplicate essentially as described (5, 10), using saturating concentrations of the
respective ligands (60 ng/ml'251TNF,'251-LT, and '25I-IFN-a; 10 ng/ml'25I-IFN-'Y) in PBS
supplemented with 2% FCS and 0.02% sodium azide. Cells (1-2 x 106 in 300 ul final
volume) were incubated with the radiolabeled cytokine for 1-2 h at 0'C and washed three
times thereafter. In each case, nonspecific binding was determined in the presence of a 200-
fold excess ofunlabeled ligand (three replicates). Saturation binding studies were performed
similarly in duplicates at different concentrations ofradiolabeled ligand (10) with subsequent
Scatchard analysis using the program "Enzfitter" (Elsevier, Biosoft, London, U.K.).
Results
Dibutyric-CAMP Reversibly Enhances TNF-R Expression in HL-60 Cells.
￿
24-h treat-
ment of HL-60 cellswith the membrane-permeable cAMP derivative dibutyric-CAMP
(DBcAMP) resulted in a drastic enhancement of 1251TNF and 1251-LT binding ca-
pacities, whereas specific binding for IFN-a and -y remained largely unaffected (Fig.
1). Scatchard analysis of binding data demonstrate an enhancement in the number
ofTNFRs with an affinity comparable to that ofuntreated control cells(Fig. 1, inset).
DBcAMP acts in a dose-dependent manner. Concentrations in the range of 40
p,M already significantly enhanced TNF binding capacity; maximum stimulation
was obtained with 0.5-1 mM of DBcAMP treatment for 24 h (data not shown). Ki-
netic analyses revealed that TNF binding starts to increase after 4-6 h of culture
in the presence of 1 mM DBcAMP, with a peak in TNFR expression after 18-24 h
(Fig. 2), and a subsequent slow decline to 70% of maximal enhancement ofTNFR
expression during the next 5 d of culture in the presence ofDBcAMP (datanot shown).
However, when PKA stimulation was abrogated after 24 h of DBcAMP treatment,
TNF binding capacity decreased to pretreatment values within 6 h (Fig. 2).
Upregulation of TNF-Rs Is Not the Consequence of TerminalDifferentiation andIsMediated
by PKA. As CAMP is known to induce cellular differentiation in HL-60 cells into
the monocyte/macrophage and/or granulocyte pathway (15), various agents inducing
differentiation were investigated for their potential to modulate TNF binding ca-pacity. In addition to DBcAMP, a significant upregulation ofTNFRs could also
be induced with butyrate and retinal (Table I) . In contrast, DMSO, IFN-,y, granu-
locyte/macrophage(GM)-CSF, andTNF itself failed to induce a significant upregu-
lation ofTNF binding capacity. As shown previously (10), PMA treatment caused
a reduction in specific TNF binding due to PKC-mediated transmodulation of the
receptors .
To ensure the central role of PKA in upregulation of TNF binding capacity, we
evaluated additional modulators ofthePKA signal pathway . These included 8-bromo-
cAMP, which in contrast to DBcAMP, cannot be metabolized to other potentially
active second messengers such as monobutyrate-CAMP and butyrate (16) . Further,
the phosphodiesterase inhibitor 3-isobutyl-l-methyl-xanthine (IBMX) was tested,
which is known to raise the intracellular level of endogenously produced cAMP by
blocking its degradation (17) . Dibutyric-cGMP(DBcGMP) served as an additional
control . As shown in Table II, the two PKA activators 8-Br-CAMP and IBMX
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FIGURE 1 . DBcAMP selec-
tively enhances TNF and LT
high affinity binding capacity.
HL-60 cells were incubated for
24 h in the absence(/) or pres-
ence of 1 mM DBcAMP (®),
followed by determination of
TNF, LT, IFN-a, and IFN-y
binding capacities. ' (Inset) :
Scatchard analysis of I211TNF
saturation binding studies per-
formed on control HL-60 cells
(A) and DBcAMP-pretreated
HL-60 cells (/) .
40F
FIGURE 2 .
￿
PKA-mediated en-
hancement of TNF-R expres-
sion is reversible. HL-60 cells
were cultured for 24 h in the
presence of 1 mM DBcAMP,
washed twice to remove the
PKA activator, and culturewas
continued . Before treatment
and during culture, at the time
points indicated, aliquots were
taken todetermine specificTNF
binding capacity.950
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TABLE I
Effect of Various Agents on TNF-R Expression in HL-60 Cells
For references, see Collins (15).
1 HL-60 cells were cultured for 24 h in the presence o£the substances indicated. Subsequent-
ly, specific TNF binding (expressed in percent ofthe untreated control; 3,600 t 1,245 TNF-
R/cell) was determined as described in Materials and Methods. Mean t SD of three in-
dependent experiments. Boldfaced numbers indicate statistically significant enhancement
(P < 0.01).
5 Significant enhancement of TNF binding capacity by retinal treatment of HL-60 cells was
only revealed upon prolonged culture (>48 h). The data shown represent maximum expres-
sion obtained after 72 h culture in the presence of retinal.
significantly enhanced the TNF-binding capacity of HL-60 cells, whereas the pro-
teinkinase Gactivator DBcGMPproved ineffective. At suboptimal concentrations,
IBMXandDBcAMPsynergistically enhanced TNFbindingcapacity(Table H, Exp.
1). The simultaneous addition ofH-8, apotent inhibitor ofprotein kinases, in par-
ticular ofPKA, completely abolished CAMP-mediatedupregulation ofTNF binding
capacity (Table H, Exp. 2). Moreover, H-8 treatment also reduced TNF binding
TABLE II
DBcAMP Enhances TNF-receptor Expression Via
Stimulation of Protein Kinase A
HL-60 cells were treated for 24 h; see footnote to Table I for details. Represen-
tative data from one of three experiments are shown.
HL-60 cells were treated for 7 h; mean of two experiments.
Exp. Substance added (concentration)
Specific
12'I-TNF-binding
capacity
1` DBcGMP (1 .0 mM) 104
8BrcAMP (5.0 mM) 262
DBcAMP (0.3 mM) 242
DBcAMP (1.0 mM) 602
IBMX (0.1 mM) 115
IBMX (1 .0 mM) 280
IBMX + DBcAMP (0.1 mM + 0.3 mM) 402
21 DBcAMP (1.0 mM) 411
H-8 (30 pM) 35
DBcAMP + H-8 (1 .0 mM + 30pM) 65
Substance
(concentration)
Induced pathway of
differentiation'
Specific TNF binding:
(percent of untreated control)
DBcAMP (1 mM) Monocyte/granulocyte 623 t 84
DMSO (I%) Granulocyte 113 t 16
Retinal (5 AM) Granulocyte 223 f 275
IFN-y (10 ng/ml) Monocyte 99 t 13
TNF (10 ng/ml) Monocyte 71 t 28
Sodium butyrate (0.5 mM) Monocyte/eosinophil 287 t 71
GM-CSF (1 Ng/ml) Eosinophil 112 ± 10
PMA (10-t° M) Macrophage 37 t 18capacity ofunstimulated HL-60 cells, indicating adirect involvement ofprotein ki-
nases in both constitutive and cAMP-enhanced TNFR expression (Table II, Exp.
2). Sensitivity tokinase inhibitors and the selectivity ofCAMP for PKA, therefore,
points to a central role of PKA in control of TNF binding capacity.
PKA Activation Results in Enhanced TNF-R Synthesis.
￿
Upregulation ofTNFbinding
capacity couldbe either due toa change in TNFR synthesis or, alternatively, might
reflect changes inthekinetics ofreceptor degradationorexport intothecellular mem-
brane. Toexploit these possibilities, we compared the basic receptor turnoverinboth
untreated and DBcAMP-treated HL-60 cells. The rate ofTNFR degradation was
examined by blockingdenovo protein synthesis withcycloheximide (CHX). Inboth
untreatedcontrol cellsand DBcAMP pretreated cells, the decrease in TNF binding
capacity followed kinetics of first order with an identical half-life ofti2 h, as indi-
cated by the parallel and linear slopes in a semilogarithmic plot (Fig. 3).
Thesedata already suggested that upregulation ofTNFRs by PKA mightreflect
a proportional enhancement in receptor synthesis rather than changes in turnover
rate. As specific TNFR probes for direct determination ofexpression at transcrip-
tional or posttranscriptional levels are not yet available, protein synthesis-depen-
dent recovery ofspecific TNF-binding capacity upon proteolytic digestion ofTNF
Rs was studied to estimate the rate of TNFR synthesis. We investigated the reex-
pression of TNFRs in HL-60 cells by determining the specific membrane TNF
bindingcapacity upon trypsin treatment, whichcaused a 70-95% reduction in func-
tional TNFRs. However, in contrast to U937 cells (10), HL-60 cells contain a
significant intracellular poolofTNFRs. Thus, initialexperimentsrevealed that upon
tryptic digestion of TNFRs, 10-40% of pretreatment TNFR levels can be tran-
siently regained in CHXpretreated (10 p.g/ml) HL-60 cells within 1 h after trypsin
treatment (datanotshown). Therefore, in furtherexperimentsthedifference inTNFR
membrane reexpression in the absence and presence of CHX was taken for evalua-
tionofreceptor denovo synthesis. Fig. 4 shows that thede novo proteinsynthesis-de-
pendent TNFR membrane expression of DBcAMP-treated cells increased eight-
fold as compared with that of the untreated control HL-60 cells.
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FIGURE 3.
￿
Identical half-lives
of TNF-receptors in untreated
and DBcAMP-treated HL-60
cells. HL-60cells were cultured
for 24 h in the presence of 1 mM
DBcAMP (/) or were left un-
treated ("). Then 10 kg/ml of
CHXwas added toboth groups
and cell culture was continued.
At the time points indicated,
specific TNF binding capacity
was determined from aliquots.
Results are given in cpm at a
semilogarithmic scale.952
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specific TNF binding (cpm " 1000)
￿
FIGURE 4.
￿
DBcAMPenhances
reexpression ofTNRR in HL-
60 cells afterproteolytic diges
tion. Control HL-60 cells (N)
andDBcAMP-stimulated (24h,
1 mM DBcAMP) HL-60 cells
(") were treated at 37°C with
0.1% trypsin for 15 min and
washed twice. The two groups
were each split into twoaliquots
forfurtherincubation in theab-
sence and presence of 10 wg/ml
of CHX, respectively. Before
and aftertrypsintreatmentand
at thesubsequent time points as
indicated, specific TNF binding
2,6
￿
capacity was determined from
time after trypsin treatment (h)
￿
aliquots of all four groups.
Specific TNFbindingcapacity
of HL-60cells wasreducedfrom
5,145 and 39,377 cpm to 1,515 and 2,688 cpm by trypsin treatment of control and DBcAMP-treated
cells, respectively.Thefiguredepictsthekinetics ofrecovery ofprotein synthesis- dependent TNFbinding,
i.e., A cpm=specific TNF binding of untreated and CHX-treated cells are plotted vs. time.
StimulationofPKA DoesNotInterfere with PKC-mediated TransmodulationofTNF-Binding
Capacity. In light of a potential crosstalk ofPKA and PKC (18), it was ofinterest
to investigate whether TNFR transmodulation by PKC is still effective under con-
ditions ofTNFR upregulation by PKA. Accordingly, HL-60 cells were either left
untreated orwere pretreated for24h with DBcAMP, and subsequently, TNF binding
capacity was determined in both groups before aswell as 0.5 and 24h aftertransient
stimulation ofPKC by pulse treatment with OAG. The data obtained revealed that
upon OAG treatment, TNFbinding capacity was reduced to a similar extent inboth
cAMP-treated (6% ofcontrol) and untreated (10% ofcontrol) HL-60 cells (Table
III). Moreover, after transient activation of PKC, TNF binding capacity reached
the respective pretreatment values within 24 h (Table III), suggesting that PKC does
TABLE III
TNF-R Transmodulation by PKC Is Equally Effective in
Untreated and DBcAMP-pretreated HL-60 Cells
` HL-60 cells, either DBcAMP-pretreatedor left untreated, were incubated at
room temperature for 30 minwith 250pM OAG, washed twice, and further
cultured for24 hin thepresence andabsence of 1 mM DBcAMP, respective-
ly. Before, directly afterOAG treatment, and at the end of the 24-h culture
period, specific TNF binding capacity was determined from aliquots.
t Specific TNFbinding capacity is givenin cpmper 106cells (%). Data shown
are derived from one representative experiment.
Time point of
binding assay`
Specific TNF
Control
binding of HL-60 cells;
DBcAMP-stimulated
OAG pulse treatment
Before 9,427 (100) 51,977 (100)
Directly after 588 (6) 5,183 (10)
24 h after 10,521 (112) 50,030 (96)SCHEURICH ET AL.
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TABLE IV
Cell-speck Sensitivity to Upregulation of TNF-R by PKA Stimulation
' Thecells were cultured for 24 hwith 1 mM DBcAMP, and subsequently, spe-
cific TNF-binding capacity was determined (given in percent of the untreated
controls; 100% = 2,600 - 14,600 cpm). Mean t SD of at least three in-
dependent experiments.
not interfere with either normal or with PKA-enhanced TNFreceptor synthesis,
but rather controls the binding affinity ofmembrane-expressed receptor molecules.
Cell Specificity ofPKA-inducedReceptor Upregulation. A number ofdifferent tumor
cell lines were investigated for DBcAMP stimulation of TNFR synthesis. 5 of 15
investigatedcelllinesofdistinct tissue origin did respond withasignificant enhance-
ment in specific TNF binding capacity; aside from two human myeloid TNF pro-
ducer cell lines, U937 and HL-60, the human erythroblastoid leukemia cell K562
as well as the murine T cell lymphoma EL4 and a human colon carcinoma cellline
(SW480) were found to be responsive (Table IV), suggesting that this mechanism
of receptor control is neither species nor strictly tissue specific. However, the data
shown in Fig. 4 suggest that PKA-mediated upregulation of TNFR expression is
particularly effective in tumor cells derived from myeloid origin. Therefore, we in-
vestigated whether in normal peripheral bloodmonocytes/macrophagesTNFR ex-
pression is also controlled by PKA. On average, purified, unstimulated monocytes
constitutively expressed "1,000 TNFR (data not shown). Similarto established cell
lines, PKAstimulationwaseffective innormal peripheral bloodmonocytes, yielding,
on average, a threefold (281 t 54%) enhancement ofTNFR (Table IV). Again,
affinity of TNFR remained unchanged upon DBcAMP treatment ofthe cells, as
indicated by the parallel slopes of the Scatchard diagram shown in Fig. 5.
Discussion
Thepresent investigations aimed at an identification ofintracellularcontrol mech-
anisms of TNFR expression, a condition requisite for TNF responsiveness. The
datashow thatactivators ofPKAcanselectivelyupregulate TNFR expression, pre-
Cell Origin Specific TNF binding'
0 /0
HL-60 Promyelocyte 688 t 122
U937 Histiocyte 262 t 82
K562 Erythroblast 172 t 34
HuT78 T cell leukemia 116 t 18
Jurkat T cell leukemia 105 t 13
Molt3 T cell leukemia 117 t 16
YT T cell leukemia 87 t 27
G1134 EBV-transformed B cell line 91 t 17
Colo205 Colon carcinoma 97 t 10
WiDR Colon carcinoma 90 t 14
SW 480 Colon carcinoma 178 t 26
HeLa Cervix carcinoma 84 t 33
WiSH Fibroblast 94 t 11
L929 Murine fibrosarcoma 100 t 11
EL4 Murine thymoma 574 t 93
Normal peripheral blood monocytes/macrophages 281 t 54954
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FIGURE 5. Enhancement of
TNF-R in peripheral mono-
cytes/macrophages by PKA
stimulation . Plastic adherent
cells were incubated in the ab-
sence (+)or presence (0)of 1
mMDBcAMPfor 24 h . Thedi-
agramshowsthe Scatchardplot
of one representative experi-
ment out ofthree (unstimulated
cells : 760 receptors/cell, Kd =
1 .05 x 10-10 M; stimulated
cells : 2,260 receptors/cell, Kd
= 1.25 x 10- I M) . (Inset)
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t cells of the myeloid lineage, whereas protein
kinase inhibitors interfere withTNFR expression . In HL-60 cells, on average, a
sevenfold stimulation was achieved after 24 h of treatment with optimal concentra
tions of DBcAMP (Table II), yielding -28,000 receptors/cell . As expected, the
binding capacity for 1251-LT was enhanced in parallel, which is in agreement with
thecurrentview ofasingle cellularmembrane receptor bindingboth cytokines (19) .
In contrast, expression of both types ofIFN receptors (u, y) proved to be insensitive
to this stimulation regimen (Fig. 1) .
Kinetics of receptor degradation after blocking of protein synthesis with CHX
was found to be of first order, suggesting that TNFR degradation might simply
reflect normal cellular membrane turnover (20) . Half-life ofTNFRs of -2 h was
identical in both CAMP-treated and untreated HL-60 cells (Fig . 3), indicating that
degradation of TNFRs increases in parallel with an increase in TNFR number
triggered by PKA stimulation. This leads to the conclusion that PKA activation
most likely causes an enhancement ofTNFR synthesis . At present, due to lack of
appropriateprobes,TNFR gene transcription and/or translation cannot be directly
analyzed . Therefore, estimates on the rate ofTNFR synthesis have to rely on the
indirect approach of quantification of protein synthesis-dependent acquisition of
TNF binding capacity. The different membrane reexpression rates upon removal
ofTNFR by trypticdigestion (Fig. 4) strongly argue forenhanced synthesis ofreceptor
proteins in cAMP-treated as compared with untreated HL-60 cells. Moreover, com-
plete recovery from PKC-mediated transmodulation ofTNFR in cAMP-treated
cells (Table III) further supports this reasoning . The latter experiments also suggest
that PKC-mediated transmodulation andPKA-mediated receptor upregulatiôn are
independent ofeach other and can be effective at thesame time, resulting in apheno-
typically antagonistic action .
Aside fromDBcAMP, sodium butyrateand retinalwere also found to upregulate
TNFRs in HL-60 cells . While retinal is known to activate PKA (21), butyrate is
thought to mainly affect histone deacetylation (22). As DBcAMP is known to be-
come processed intracellularly, resulting in the release of monobutyric cAMP and
butyrate (16), it is conceivable that DBcAMP is effective exclusively via intracellularSCHEURICH ET AL.
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release ofbutyrate and not via activation ofPKA. The latter possibility could be
excluded, as8-Br-CAMP, an additional activator ofPKA, and IBMX, an inhibitor
ofdegradation ofendogenously produced CAMP (17), also enhanced TNF binding
capacity, whereas DBcGMP was ineffective. Moreover, H-8, a potent inhibitor of
PKA, completely abolishedCAMP upregulation ofTNFR(Table 11). WhetherCAMP
andbutyrate enhance TNFRexpression via shared signal pathways oract completely
independent of each other, is unknown at present.
Since DBcAMP, retinal, and butyric acid are known to induce differentiation in
HL-60 cells (15), upregulation ofTNFR expression in these cells might represent
a consequence of an altered differentiation status triggered by these various agents.
However, in regard toTNFR expression, both DBcAMP (Fig. 2) and butyrate ac-
tion(datanot shown) werefully reversible. Furthermore, maximum effectsofDBcAMP
and butyrate were observed after 24 h of treatment, at which time only N5% of
the HL-60 cells are considered to be differentiated (23). Apparently, enhancement
of TNFRs is not linked to irreversible processes of cellular differentiation. These
suggestions aresupported bythe findingthatTNFRsare upreguaated by activation
ofPKA in tumor cell lines ofmyeloidorigin and in normal peripheral blood mono-
cytes/macrophages representing various stages of the myelomonocytic differentia-
tion pathway (Table IV, Fig. 5). Various activators of PKA as well as IBMX were
also effective in these cells (data not shown) .
Recent work from our laboratory (24, 25) and from others (26) provided evidence
that production ofTNF itself is also controlled by protein kinases. Thus, activation
ofPKC leads to induction ofTNF mRNA and/or secretion ofthe protein (24, 25).
PKA, on the other hand, has been demonstrated to act as a negative regulator on
TNF production (26). These effects are exactly opposed to those of the respective
proteinkinase onTNFRsynthesis(PKA)anditsfunctional status (PKC). Asshown
here, both mechanismscanbe effective in asingle cell type, thatisperseTNF sensi-
tive and a potential TNF producer, such as normal peripheral blood monocytes as
well as the monocytec cell lines HL-60 and U937 (5, 6, 27, 28). Moreover, as both
protein kinases apparently participate in TNF signal transduction (7, 24, 29), we
suggest that a regulatory circuit could be effective in the following way: activation
ofPK-A results in an enhancement ofTNFR expression paralleled with inhibition
ofTNFproduction; on the other hand, activation ofPKC induces production and
secretion ofmature (17 kD) TNF and simultaneously inactivates expressed TNF
membrane receptors (transmodulation), thereby inducing TNF resistance (10). As
TNFRs areubiquitously expressed (4, 5)and manydifferentcell typesare potential
TNF producers (24, 30-32), such an antagonistically acting regulatory circuit may
be used tocontrol autocrine stimulation, and may enable cellstocompletely switch
from a signal transmitter (TNF producer) to a receiver (TNF responder) status.
Summary
We have investigated control mechanisms ofTNF receptor expression (TNFR)
in various human tumor cells and normal peripheral blood monocytes. Activators
ofproteinkinase A(PKA) signal transductionpathways were foundtoenhanceTNFR
expression up to sevenfold, whereas in the same cells, IFN-C1 and -y receptors re-
mained unaffected. Inhibitorsofprotein kinases downregulate both constitutive and
CAMP-enhanced TNFR expression. Binding studies revealed an increase in TNF956
￿
CONTROL OF TUMOR NECROSIS FACTOR RECEPTORS
R numbers without a change in receptor affinity. Both, direct activators of PKA
and inhibitors ofphosphodiesterase, raising intracellular levels ofCAMP, were found
to be effective. As activation of PKA does not slow down the degradation rate of
TNFRs, but rather enhances protein synthesis-dependent reexpression ofTNFRs
after transient PKC-mediated transmodulation and after tryptic digestion of TNF
Rs, it is concluded that PKA stimulates TNFR synthesis. Maximum TNFRs en-
hancement is reached after 24 h of stimulation and is reversible, suggestingthat receptor
upregulation is not linked to irreversible steps ofcellular differentiation. PKA-mediated
enhancement ofTNFR expression was predominantly observed in normal periph-
eral blood monocytes and tumorcell lines of myeloid origin. As in these typical TNF
producer cells, the production ofTNF is also controlled by PKA and PKC, a regulatory
circuit is proposed, by which these two independent signal pathways antagonisti-
cally regulate TNF production and, at the receptor level, TNF sensitivity.
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